Last reviewed · How we verify
Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.
This is a phase IIa, double-blind, randomised, placebo-controlled, multi-center study to evaluate the effects of estetrol on testosterone suppression and quality of life in prostate cancer patients treated with an LHRH agonist. Patients will be treated with estetrol or placebo for 6 months.
Details
| Lead sponsor | Pantarhei Oncology B.V. |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 63 |
| Start date | Mon Apr 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri May 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Prostatic Neoplasm
Interventions
- Estetrol
- Placebo Oral Tablet
Countries
Netherlands